Terms ending in 2031
Every in-force patent on Genmab A/S's record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,657,107 | Monoclonal Antibodies Against C-Met In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,085,625 | Antibody Variants Having Modifications In The Constant Region In force · High confidence | Genmab A/S | In force | High confidence | |
| US 8,802,089 | Monoclonal Antibodies Against CD32B In force · High confidence | Genmab A/S | In force | High confidence | |
| US 8,529,902 | Human Monoclonal Antibodies Against CD20 In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,150,663 | Heterodimeric Antibody Fc-Containing Proteins and Methods for Production Thereof In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,597,464 | Heterodimeric Antibody Fc-Containing Proteins and Methods for Production Thereof In force · Low confidence | Genmab A/S | In force | Low confidence | |
| US 9,944,711 | Antibodies Against Human CD38 In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,068,011 | Monoclonal Antibodies Against C-Met In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,168,314 | Human Antibody Drug Conjugates Against Tissue Factor In force · Medium confidence | Genmab A/S | In force | Medium confidence | |
| US 9,249,226 | Antibodies Against Human CD38 In force · High confidence | Genmab A/S | In force | High confidence |
10 of 10 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.